Insider Selling: Phreesia (NYSE:PHR) SVP Sells 2,602 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP Amy Beth Vanduyn sold 2,602 shares of Phreesia stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $17.01, for a total transaction of $44,260.02. Following the completion of the transaction, the senior vice president directly owned 160,238 shares of the company’s stock, valued at approximately $2,725,648.38. This represents a 1.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Amy Beth Vanduyn also recently made the following trade(s):

• On Friday, October 17th, Amy Beth Vanduyn sold 639 shares of Phreesia stock. The stock was sold at an average price of $22.36, for a total transaction of $14,288.04.

Phreesia Stock Performance

Shares of NYSE PHR traded down $0.10 during midday trading on Monday, hitting $17.14. The company’s stock had a trading volume of 760,277 shares, compared to its average volume of 1,018,096. Phreesia, Inc. has a 1-year low of $15.41 and a 1-year high of $32.76. The firm’s fifty day moving average price is $18.95 and its 200-day moving average price is $23.69. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The firm has a market cap of $1.03 billion, a P/E ratio of -171.33 and a beta of 0.61.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Monday, December 8th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.11. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The firm had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. During the same quarter in the prior year, the business earned ($0.25) earnings per share. Phreesia’s quarterly revenue was up 12.7% on a year-over-year basis. On average, sell-side analysts forecast that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Investors Weigh In On Phreesia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PHR. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Phreesia by 108.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,644,988 shares of the company’s stock worth $67,606,000 after buying an additional 1,377,904 shares during the period. Loomis Sayles & Co. L P purchased a new stake in shares of Phreesia in the 2nd quarter valued at approximately $34,162,000. Millennium Management LLC lifted its position in shares of Phreesia by 730.7% in the 3rd quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after acquiring an additional 936,033 shares in the last quarter. Greenhouse Funds LLLP boosted its stake in Phreesia by 16.8% in the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock worth $91,317,000 after purchasing an additional 557,265 shares during the period. Finally, Bessemer Group Inc. grew its position in Phreesia by 1,065.9% during the 3rd quarter. Bessemer Group Inc. now owns 554,513 shares of the company’s stock worth $13,043,000 after purchasing an additional 506,954 shares in the last quarter. Institutional investors own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. KeyCorp reduced their price objective on Phreesia from $35.00 to $32.00 and set an “overweight” rating for the company in a research report on Wednesday, October 8th. JPMorgan Chase & Co. lowered their price target on shares of Phreesia from $32.00 to $29.00 and set an “overweight” rating for the company in a research report on Tuesday, December 9th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a report on Friday, October 31st. BMO Capital Markets assumed coverage on shares of Phreesia in a research note on Thursday, November 13th. They set an “outperform” rating and a $32.00 target price for the company. Finally, Royal Bank Of Canada started coverage on shares of Phreesia in a research report on Friday. They issued an “outperform” rating and a $26.00 target price for the company. Seventeen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $30.06.

Phreesia Company Profile

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.